{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:06:38Z","timestamp":1791324398070,"version":"4.3.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jdcr.2022.07.011","type":"journal-article","created":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T06:06:51Z","timestamp":1657951611000},"page":"114-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Obinutuzumab in a patient with chronic lymphocytic leukemia-associated paraneoplastic pemphigus"],"prefix":"10.1016","volume":"27","author":[{"given":"Johanna","family":"Freund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Trautinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Kopetzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Prillinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdcr.2022.07.011_bib1","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1056\/NEJM199012203232503","article-title":"Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia","volume":"323","author":"Anhalt","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdcr.2022.07.011_bib2","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3389\/fimmu.2019.01259","article-title":"Paraneoplastic pemphigus: paraneoplastic autoimmune disease of the skin and mucosa","volume":"10","author":"Kim","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jdcr.2022.07.011_bib3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1046\/j.1523-1747.1998.00280.x","article-title":"Autoantibodies from a patient with paraneoplastic pemphigus bind periplakin, a novel member of the plakin family","volume":"111","author":"Borradori","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jdcr.2022.07.011_bib4","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1046\/j.1523-1747.1998.00449.x","article-title":"Envoplakin and periplakin are components of the paraneoplastic pemphigus antigen complex","volume":"111","author":"Kiyokawa","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jdcr.2022.07.011_bib5","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/cup.14004","article-title":"Paraneoplastic pemphigus: revised diagnostic criteria based on literature analysis","volume":"48","author":"Svoboda","year":"2021","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jdcr.2022.07.011_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1087-0024.2004.00832.x","article-title":"Paraneoplastic pemphigus","volume":"9","author":"Anhalt","year":"2004","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1016\/j.jdcr.2022.07.011_bib7","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.2169\/internalmedicine.0578-17","article-title":"Paraneoplastic pemphigus associated with B-cell chronic lymphocytic leukemia treated with ibrutinib and rituximab","volume":"57","author":"Ito","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.jdcr.2022.07.011_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.15232","article-title":"A tale of two antibodies: obinutuzumab versus rituximab","volume":"182","author":"Freeman","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jdcr.2022.07.011_bib9","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s12325-016-0451-1","article-title":"A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies","volume":"34","author":"Tobinai","year":"2017","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.jdcr.2022.07.011_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2021.100813","article-title":"Successful treatment of paraneoplastic pemphigus and bronchiolitis obliterans associated with follicular lymphoma with obinutuzumab and bendamustine","volume":"46","author":"Kuriyama","year":"2022","journal-title":"Curr Probl Cancer"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512622003174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512622003174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:24:47Z","timestamp":1762475087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512622003174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":10,"alternative-id":["S2352512622003174"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2022.07.011","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obinutuzumab in a patient with chronic lymphocytic leukemia-associated paraneoplastic pemphigus","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2022.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}